A phase 1 study of ACE‐536, a regulator of erythroid differentiation, in healthy volunteers
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
ACE‐536, a recombinant protein containing a modified activin receptor type IIB, is being developed for the treatment of anemias caused by ineffective erythropoiesis, such as thalassemias and myelodysplastic syndromes. ACE‐536 acts through a mechanism distinct from erythropoiesis‐stimulating agents to promote late‐stage erythroid differentiation by binding to transforming growth factor‐β superfamily ligands and inhibiting signaling through transcription factors Smad 2/3. The goal of this Phase 1 study was to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of ascending dose levels of ACE‐536 in healthy volunteers. Thirty‐two postmenopausal women were randomized in sequential cohorts of eight subjects each to receive up to two doses of either ACE‐536 (0.0625–0.25 mg/kg) or placebo (3:1 randomization) given subcutaneously every 2 weeks. Mean baseline age was 59.4 years, and hemoglobin was 13.2 g/dL. ACE‐536 was well tolerated at dose levels up to 0.25 mg/kg over the 1‐month treatment period. There were no serious or severe adverse events, nor clinically meaningful changes in safety laboratory measures or vital signs. Mean ACE‐536 AUC 0–14d and Cmax increased proportionally after first dose; mean t½ was 15–16 days. Dose‐dependent increases in hemoglobin concentration were observed, beginning 7 days after initiation of treatment and maintained for several weeks following treatment. The proportion of subjects with a hemoglobin increase ≥1.0 g/dL increased in a dose‐dependent manner to 83.3% of subjects in the highest dose group, 0.25 mg/kg. ACE‐536 was well tolerated and resulted in sustained increases in hemoglobin levels in healthy postmenopausal women. Am. J. Hematol. 89:766–770, 2014. © 2014 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1999) · Nature Genetics · doi:10.1038/10320 · Cited by 471 · cited 5×
“Thus, the mechanism of action of ACE-536 may be via binding to other ligands, including GDF11 [8–10], resulting in reduced Smad 2/3 signaling [10,14].”
BackgroundInfluentialAn activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia
Dussiot, M., Maciel, T. T., Fricot, A., Chartier, C., Negre, O., Veiga, J., Grapton, D., Paubelle, E., Payen, E., Beuzard, Y., et al. (2014) · Nature Medicine · doi:10.1038/nm.3468 · Cited by 279
Ginzburg, Y., & Rivella, S. (2011) · Blood · doi:10.1182/blood-2011-03-283614 · Cited by 201
Sako, D., Grinberg, A. V., Liu, J., Davies, M. V., Castonguay, R., Maniatis, S., Andreucci, A. J., Pobre, E. G., Tomkinson, K. N., Monnell, T. E., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.114959 · Cited by 152 · cited 1×
“[10,14].”
Cited by
A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia.
Cappellini, M. D., Viprakasit, V., Taher, A. T., Georgiev, P., Kuo, K. H. M., Coates, T., Voskaridou, E., Liew, H.-K., Pazgal-Kobrowski, I., Forni, G. L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910182 · Cited by 332
Self-citationPlatzbecker, U., Germing, U., Götze, K. S., Kiewe, P., Mayer, K., Chromik, J., Radsak, M., Wolff, T., Zhang, X., Laadem, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30615-0 · Cited by 292
Self-citationPiga, A., Perrotta, S., Gamberini, M. R., Voskaridou, E., Melpignano, A., Filosa, A., Caruso, V., Pietrangelo, A., Longo, F., Tartaglione, I., et al. (2019) · Blood · doi:10.1182/blood-2018-10-879247 · Cited by 119
Self-citationA comprehensive joint analysis of the long and short RNA transcriptomes of human erythrocytes.
Doss, J. F., Corcoran, D. L., Jima, D. D., Telen, M. J., Dave, S. S., & Chi, J.-T. (2015) · BMC Genomics · doi:10.1186/s12864-015-2156-2 · Cited by 113
Targeting Immune Signaling Pathways in Clonal Hematopoiesis
Azrakhsh, N. A., Mensah-glanowska, P., Sand, K., & Kittang, A. O. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190325100636 · Cited by 8
Metadata
- Authors
- Attie, K. M., Allison, M. J., McClure, T., Boyd, I. E., Wilson, D. M., Pearsall, A. E., & Sherman, M. L.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2014-04-26
- Volume
- 89
- Issue
- 7
- Pages
- 766-770
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W1499045657
- Cited by
- 111
- References
- 4
- FWCI
- 4.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase 1 study of ACE‐536, a regulator of erythroid differentiation, in healthy volunteers. https://app.cochat.ai/papers/10.1002/ajh.23732
- The paper
- Attie, K. M., Allison, M. J., McClure, T., Boyd, I. E., Wilson, D. M., Pearsall, A. E., & Sherman, M. L. (2014). A phase 1 study of ACE‐536, a regulator of erythroid differentiation, in healthy volunteers. American Journal of Hematology. https://doi.org/10.1002/ajh.23732
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.